Stay updated on SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the 4SC-202 and pembrolizumab melanoma study is now available, with details about the completed trial, participant criteria, study locations, and measured outcomes.
    Difference
    42%
    Check dated 2026-11-08T15:18:10.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T16:29:16.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A notice was added explaining that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” across its content.
    Difference
    1%
    Check dated 2026-10-25T16:29:13.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-18T20:42:17.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T20:48:38.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Access to the study record now returns a 403 Forbidden error instead of loading the study details. This indicates a permission or server issue rather than a content update.
    Difference
    17%
    Check dated 2026-09-20T20:20:39.000Z thumbnail image

Stay in the know with updates to SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.